Global Inhalation and Nasal Spray Generic Drugs Market by Indications, Therapeutic Classes and Forecast to 2020, New Findings by iHealthcareAnalyst, Inc.
Inhalation and Nasal Spray Generic Drugs Market by Indication Type (Allergic Rhinitis, Asthma, COPD), Therapeutic Drug Classes (Antihistamines, Bronchodilators – Albuterol, Epinephrine; Combination Drugs – Azelastine (Benzalkonium Chloride), Formoterol (Budesonide), Salmeterol (Fluticasone); Corticosteroids – Beclomethasone, Budesonide, Flunisolide, Fluticasone; Decongestant Sprays – Phenylephrine and Oxymetazoline Hydrochlorides) 2016-2020
Maryland Heights, MO, March 17, 2017 --(PR.com)-- The global inhalation and nasal spray generic drugs market is estimated to reach USD 32 Billion in 2020, growing at a CAGR of 6.8% from 2016 to 2020 due to lower cost prescription drugs and increase in respiratory diseases worldwide.
Browse Inhalation and Nasal Spray Generic Drugs Market by Indication Type (Allergic Rhinitis, Asthma, COPD), Therapeutic Drug Classes (Antihistamines, Bronchodilators – Albuterol, Epinephrine; Combination Drugs – Azelastine (Benzalkonium Chloride), Formoterol (Budesonide), Salmeterol (Fluticasone); Corticosteroids – Beclomethasone, Budesonide, Flunisolide, Fluticasone; Decongestant Sprays – Phenylephrine and Oxymetazoline Hydrochlorides) 2016-2020 report at https://www.ihealthcareanalyst.com/report/inhalation-nasal-spray-generic-drugs-market/
Intranasal medication delivery is important for both specifically developed pharmaceutical drugs designed for intranasal treatment, as well as for investigating off label uses of commonly available generic medications. Nasal sprays for local effect are quite common. Steroids, antiasthma medications such as salbutamol, ipratropium, montelukast and a large number of inhalational anaesthetic agents are being commonly used. Increase in the incidence of chronic obstructive pulmonary disease, asthma, and other fatal respiratory disorders are driving the global inhalation and nasal spray generic drugs market.
The global inhalation and nasal spray generic drugs market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the indication type (allergic rhinitis, asthma, COPD, etc.), therapeutic drug classes (antihistamines, bronchodilators – albuterol, epinephrine; combination drugs - Azelastine (benzalkonium chloride), Formoterol (budesonide), Salmeterol (fluticasone); Corticosteroids – beclomethasone, budesonide, flunisolide, fluticasone; decongestant sprays – phenylephrine and oxymetazoline hydrochlorides), and forecasts growth trends (CAGR% - 2016 to 2020). The global inhalation and nasal spray generic drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global inhalation and nasal spray generic drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global inhalation and nasal spray generic drugs market and included in this report are Teva Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Allergan plc, Mylan N.V., Ranbaxy Laboraotries Ltd., Roxane Laboratories, Inc., Beximco Pharmaceuticals Ltd., Cipla Ltd., and Nephron Pharmaceuticals Corporation.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/inhalation-nasal-spray-generic-drugs-market/
About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Browse Inhalation and Nasal Spray Generic Drugs Market by Indication Type (Allergic Rhinitis, Asthma, COPD), Therapeutic Drug Classes (Antihistamines, Bronchodilators – Albuterol, Epinephrine; Combination Drugs – Azelastine (Benzalkonium Chloride), Formoterol (Budesonide), Salmeterol (Fluticasone); Corticosteroids – Beclomethasone, Budesonide, Flunisolide, Fluticasone; Decongestant Sprays – Phenylephrine and Oxymetazoline Hydrochlorides) 2016-2020 report at https://www.ihealthcareanalyst.com/report/inhalation-nasal-spray-generic-drugs-market/
Intranasal medication delivery is important for both specifically developed pharmaceutical drugs designed for intranasal treatment, as well as for investigating off label uses of commonly available generic medications. Nasal sprays for local effect are quite common. Steroids, antiasthma medications such as salbutamol, ipratropium, montelukast and a large number of inhalational anaesthetic agents are being commonly used. Increase in the incidence of chronic obstructive pulmonary disease, asthma, and other fatal respiratory disorders are driving the global inhalation and nasal spray generic drugs market.
The global inhalation and nasal spray generic drugs market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the indication type (allergic rhinitis, asthma, COPD, etc.), therapeutic drug classes (antihistamines, bronchodilators – albuterol, epinephrine; combination drugs - Azelastine (benzalkonium chloride), Formoterol (budesonide), Salmeterol (fluticasone); Corticosteroids – beclomethasone, budesonide, flunisolide, fluticasone; decongestant sprays – phenylephrine and oxymetazoline hydrochlorides), and forecasts growth trends (CAGR% - 2016 to 2020). The global inhalation and nasal spray generic drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global inhalation and nasal spray generic drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global inhalation and nasal spray generic drugs market and included in this report are Teva Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Allergan plc, Mylan N.V., Ranbaxy Laboraotries Ltd., Roxane Laboratories, Inc., Beximco Pharmaceuticals Ltd., Cipla Ltd., and Nephron Pharmaceuticals Corporation.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/inhalation-nasal-spray-generic-drugs-market/
About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Contact
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 500-7508
https://www.ihealthcareanalyst.com/
Ana Aitawa
(314) 500-7508
https://www.ihealthcareanalyst.com/
Contact
Categories